In the News

IPA News

June 25th, 2024

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™

VICTORIA, BRITISH COLUMBIA (CANADA), June 25, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating...

June 10th, 2024

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

-BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. ...

IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology

VICTORIA, British Columbia May 30, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has...

Connect with IPA

Follow us on LinkedIn Contact Us